Abstract
Background
Temozolomide (TMZ) is widely used in Europe and the United States. For the safe use of TMZ in the Japanese, as representative of Asians, the pharmacokinetics of TMZ was investigated in Japanese patients and compared to that in Caucasians.
Methods
The pharmacokinetics and safety of TMZ following oral administration of 150 and 200 mg/m2 per day for the first 5 days of a 28-day treatment cycle were investigated in six Japanese patients with relapsed gliomas.
Results
The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t1/2λz) was about 2 h. A dose-dependent increase was observed in maximum plasma concentration (Cmax) and AUC, while values for t1/2λz, apparent total body clearance (CL/F), and apparent distribution volume (Vz/F) were independent of dose. After administration for 5 days, changes in pharmacokinetics and accumulation were not observed. The plasma 5-(3-methyl)1-triazen-1-yl-imidazole-4-carboxamide (MTIC) concentration changed in parallel with the TMZ plasma concentration, and the Cmax and AUC of MTIC were about 2% of those of TMZ. The pharmacokinetic parameters of TMZ and MTIC in Japanese patients in this study were comparable to those previously determined in Caucasian subjects. Adverse events occurred in all patients, but toxicities were mostly mild or moderate, and continuation of administration was possible by adjusting the dose and by delaying the start of the next treatment cycle.
Conclusion
The pharmacokinetic and safety profile of TMZ in Japanese patients was comparable to that in Caucasians. The treatment regimen used in Europe and the United States will be suitable for Asian patients, including Japanese.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
JA Slack C Goddard MFG Stevens et al. (1986) ArticleTitleThe analysis and murine pharmacokinetics of a new antitumor agent: CCRG 81045 J Pharm Pharmacol 38 63
RT Wheelhouse MFG Stevens (1993) ArticleTitleDecomposition of the antitumor drug temozolomide in deuteruated phosphate buffer: methyl group transfer is accompanied by deuterium exchange J Chem Soc Chem Commun 15 1177–1178 Occurrence Handle10.1039/c39930001177
BJ Denny RT Wheelhouse MFG Stevens et al. (1994) ArticleTitleNMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 9045–9051 Occurrence Handle8049205 Occurrence Handle10.1021/bi00197a003 Occurrence Handle1:CAS:528:DyaK2cXkvF2hsbs%3D
MFG Stevens JA Hickman SP Langdon et al. (1987) ArticleTitleAntitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045: M&B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 5846–5852 Occurrence Handle3664486 Occurrence Handle1:CAS:528:DyaL1cXmvVemtQ%3D%3D
ES Newlands MFG Stevenst SR Wedge et al. (1997) ArticleTitleTemozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35–61 Occurrence Handle9189180 Occurrence Handle10.1016/S0305-7372(97)90019-0 Occurrence Handle1:CAS:528:DyaK2sXktFOrt7w%3D
S Ostermann C Csajka T Buclin et al. (2004) ArticleTitlePlasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients Clin Cancer Res 10 3728–3736 Occurrence Handle15173079 Occurrence Handle10.1158/1078-0432.CCR-03-0807 Occurrence Handle1:CAS:528:DC%2BD2cXksVKntrw%3D
ES Newlands GRP Blackledge JA Slack et al. (1992) ArticleTitlePhase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer 65 287–291 Occurrence Handle1739631 Occurrence Handle1:STN:280:By2C2MzmvFA%3D
M Brada I Judson P Beale et al. (1999) ArticleTitlePhase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies Br J Cancer 81 1022–1030 Occurrence Handle10576660 Occurrence Handle10.1038/sj.bjc.6690802 Occurrence Handle1:CAS:528:DyaK1MXnvFSjsLw%3D
MA Rudek RC Donehouwer P Statkevich et al. (2004) ArticleTitleTemozolomide in patients with advanced cancer: phase I and pharmacokinetic study Pharmacotherapy 24 16–25 Occurrence Handle14740784 Occurrence Handle10.1592/phco.24.1.16.34800 Occurrence Handle1:CAS:528:DC%2BD2cXht1SnurY%3D
P Beale I Judson S Moore et al. (1999) ArticleTitleEffect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide Cancer Chemother Pharmacol 44 389–394 Occurrence Handle10501912 Occurrence Handle10.1007/s002800050994 Occurrence Handle1:CAS:528:DyaK1MXmsVWlu7k%3D
P Kleihues DN Louis BW Scheithauer et al. (2002) ArticleTitleThe WHO classification of tumors of the nervous system J Neuropathol Exp Neurol 61 215–225 Occurrence Handle11895036
LA Hammond JR Eckardt SD Baker et al. (1999) ArticleTitlePhase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies J Clin Oncol 17 2604–2613 Occurrence Handle10561328 Occurrence Handle1:CAS:528:DyaK1MXltlyltLk%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Aoki, T., Nishikawa, R., Mizutani, T. et al. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. Int J Clin Oncol 12, 341–349 (2007). https://doi.org/10.1007/s10147-007-0687-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-007-0687-5